CNBC   |  August 25, 2014

Roche CEO: InterMune perfect strategic fit

CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.

Share This:

Sorry, we do not have a transcript available for this video at this time.